WE selected IP10 combined with IL-8 cytokines (S2/S0, ratio of changes at 10–12 weeks after treatment to baseline) to predict the response to immunotherapy combined with chemotherapy and evaluate the survival of 67 patients with lung cancer and 24 patients with mixed cancer. This evidence concerns the gene CXCL10 and lung carcinoma.